<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03245827</url>
  </required_header>
  <id_info>
    <org_study_id>28389</org_study_id>
    <nct_id>NCT03245827</nct_id>
  </id_info>
  <brief_title>Hypogonadotropic Hypogonadism in Obese Young Males</brief_title>
  <official_title>Hypogonadotropic Hypogonadism in Obese Young Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandeep Singh Dhindsa, M.D., F.A.C.E</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Louis University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity can lead to low testosterone concentrations in young men. This study will study the&#xD;
      effects of low testosterone in those men and the result of treating them with clomiphene.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of obesity has increased in children over the past few decades. Approximately&#xD;
      20% of adolescent boys are now considered obese. It is well accepted that obese children are&#xD;
      at increased risk for high blood pressure, lipid abnormalities and type 2 diabetes. Recent&#xD;
      studies have uncovered yet another undesirable effect of obesity. The testosterone levels of&#xD;
      obese boys are only half those of lean boys at completion of puberty. Testosterone is&#xD;
      important for muscle and bone development. Men with low testosterone are at higher risk of&#xD;
      insulin resistance and inflammation, which lead to type 2 diabetes and heart disease. Since&#xD;
      testosterone is the major reproductive hormone, these obese boys are at risk of decreased&#xD;
      fertility. Men are supposed to achieve their peak testosterone levels at puberty. Thereafter,&#xD;
      there is a decline in testosterone levels at the rate of 2% per year for the rest of life.&#xD;
      Thus there is a clear need to develop a deeper understanding of low testosterone in these&#xD;
      males who are entering their peak fertility years. There are no approved treatments for this&#xD;
      disorder. The investigators propose to conduct a randomized placebo controlled trial to&#xD;
      evaluate the effect of treatment with clomiphene in obese young men(age 18-30 years) who have&#xD;
      low testosterone concentrations. Clomiphene is a drug that increases testosterone&#xD;
      concentrations and possibly increases sperm production. In contrast, testosterone replacement&#xD;
      therapy decreased fertility and cannot be used in young men. Investigators will study the&#xD;
      effect of treatment with clomiphene or placebo tablets for 12 weeks in 30 subjects. The study&#xD;
      will evaluate:-&#xD;
&#xD;
        1. testicular function: Testosterone and two proteins secreted by testis(insulin like&#xD;
           factor 3 and inhibin B) will be measured in the blood before and after treatment with&#xD;
           clomiphene or placebo.&#xD;
&#xD;
        2. insulin resistance: Investigators will measure insulin and glucose levels in the blood.&#xD;
&#xD;
        3. inflammation: Investigators will measure proteins that induce inflammation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in serum testosterone</measure>
    <time_frame>12 weeks</time_frame>
    <description>after clomiphene or placebo treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in insulin like factor 3</measure>
    <time_frame>12 weeks</time_frame>
    <description>after clomiphene or placebo treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in inhibin B</measure>
    <time_frame>12 weeks</time_frame>
    <description>after clomiphene or placebo treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in insulin resistance (HOMA-IR)</measure>
    <time_frame>12 weeks</time_frame>
    <description>after clomiphene or placebo treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in nflammation</measure>
    <time_frame>12 weeks</time_frame>
    <description>after clomiphene or placebo treatment</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hypogonadism, Hypogonadotropic</condition>
  <arm_group>
    <arm_group_label>Obese males with hypogonadism-active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be randomized to receive clomiphene capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese males with hypogonadism-placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be randomized to receive placebo capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese males with normal testosterone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>comparison group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lean males with normal testosterone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>comparison group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clomiphene</intervention_name>
    <description>clomiphene capsule 25mg twice a week</description>
    <arm_group_label>Obese males with hypogonadism-active</arm_group_label>
    <other_name>active</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo capsule 25mg twice a week</description>
    <arm_group_label>Obese males with hypogonadism-placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males&#xD;
&#xD;
          -  Age 18-30 years inclusive will be recruited.&#xD;
&#xD;
        A total of 90 males will be recruited:-&#xD;
&#xD;
          -  30 obese males (defined as BMI â‰¥30 kg/m2) with HH,&#xD;
&#xD;
          -  30 obese males with normal FT concentrations and&#xD;
&#xD;
          -  30 lean males (defined as BMI &lt;25 kg/m2) with normal FT concentrations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of androgens, clomiphene, hCG, aromatase inhibitors or over the counter health&#xD;
             supplements which contain androgens currently or in the past 6 months&#xD;
&#xD;
          -  Hematocrit &gt; 50%&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  currently suffering from depression&#xD;
&#xD;
          -  type 1 diabetes&#xD;
&#xD;
          -  Hepatic disease (transaminase &gt; 3 times normal) or cirrhosis&#xD;
&#xD;
          -  Renal impairment (eGFR&lt;30 ml/min/1.73m2)&#xD;
&#xD;
          -  HIV or Hepatitis C positive status&#xD;
&#xD;
          -  Participation in any other concurrent clinical trial&#xD;
&#xD;
          -  currently suffering from foot ulcer, significant periodontal disease or any other&#xD;
             chronic infectious condition&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>males</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>sandeep dhindsa, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Louis University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandeep S dhindsa, MD</last_name>
    <phone>3149774911</phone>
    <email>sandeep.dhindsa@health.slu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Saint Louis Univeristy</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobby Campbell</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 3, 2017</study_first_submitted>
  <study_first_submitted_qc>August 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2017</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>St. Louis University</investigator_affiliation>
    <investigator_full_name>Sandeep Singh Dhindsa, M.D., F.A.C.E</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clomiphene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

